Home
GLYCOGENE
About Glycogene
Our Facilities & Team
What We Offer
Product
mRNA Raw Materials
Oligo Synthesis Raw Materials
Glycoscience
Diagnostic Reagents
Service
Custom Services
R & D Capability
Quality systems
Facilities
Blog
Company Blog
Industry Blog
Resource
Contact
Contact Us
Language
English
中文
Products
News
Storage conditions: -20℃
Key words:
Storage conditions: Keep in a dark and dry place
(Science and Technology Daily) Although researchers have made significant progress in the development of molecular therapies in recent years, the number of newly discovered active substances remains insufficient. Now, the DNA-encoded chemical library (DEL) technology, jointly developed by Harvard University in the US and ETH Zurich in Switzerland, offers a new solution. The technology can automate the synthesis and testing of billions of compounds in a matter of weeks, and can also be used to produce larger drug molecules that will act on targets that are difficult to reach with traditional small molecules.
Key words:numberprotein.
Recently, Glycogene received a confirmation letter from the U.S. Food and Drug Administration (FDA) stating that the company's submitted products, 5'-O-DMT-2'-O-methyluridine 3'-CE-Phosphoramidite (Um) and 5'-O-DMT-2'-deoxy-2'-fluorouridine-3'-CE Phosphoramidite (Uf), have officially completed the Drug Master File (DMF) filing with the FDA. This marks the first time globally that phosphoramidite monomer products have completed DMF filing with the FDA.
Key words:itemnumber
Recently, Glycogene received a confirmation letter from the U.S. Food and Drug Administration (FDA) stating that all 8 phosphoramidite monomer products submitted by the company have officially completed the Drug Master File (DMF) filing with the FDA. This marks the first time globally that phosphoramidite monomer products have completed DMF filing with the FDA. The 8 products submitted are part of the 2'-O-Me and 2'-F series, which are frequently used in small nucleic acid drugs.
